What's in Merz North America, Inc.'s pipeline?

Merz North America, Inc. has 10 drugs in our index: 5 marketed, 0 filed, 5 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Merz North America, Inc.'s portfolio?

Top competitors by shared drug class: Galderma R&D, Bayer, Brigitte Schürch, Carruthers Dermatology Centre, Department of Medical Services Ministry of Public Health of Thailand.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/merz-north-america-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Merz North America, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Merz North America, Inc. pipeline: 5 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 5 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Naftin Cream	Naftin Cream	marketed
NAFT500 (pediatric)	NAFT500 (pediatric)	marketed	Allylamine antifungal	Squalene epoxidase	Dermatology / Infectious Disease
NAFT600 (pediatric)	NAFT600 (pediatric)	marketed	Topical antifungal (allylamine)	Squalene epoxidase (fungal)	Dermatology
NAFT500 (adult)	NAFT500 (adult)	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)	Aesthetics / Dermatology
NAFT600 (adult)	NAFT600 (adult)	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)	Aesthetics; Neurology
Placebo 2-weeks	Placebo 2-weeks	phase 3
Naftin 1% Cream	Naftin 1% Cream	phase 3	Allylamine antifungal	Squalene epoxidase	Dermatology
NAFT-500	NAFT-500	phase 3	Benzylamine antifungal	Fungal sterol synthesis (squalene epoxidase inhibition)	Dermatology
NAFT-600 ( naftin 2 % gel )	NAFT-600 ( naftin 2 % gel )	phase 3	Allylamine antifungal	Squalene epoxidase	Dermatology
Placebo 4-weeks	Placebo 4-weeks	phase 3

Therapeutic area mix

Dermatology · 4
Aesthetics / Dermatology · 1
Aesthetics; Neurology · 1
Dermatology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 2 shared drug classes
Bayer · 1 shared drug class
Brigitte Schürch · 1 shared drug class
Carruthers Dermatology Centre · 1 shared drug class
Department of Medical Services Ministry of Public Health of Thailand · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Huons Co., Ltd. · 1 shared drug class
ATGC Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Merz North America, Inc.:

Cite this brief

Drug Landscape (2026). Merz North America, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/merz-north-america-inc. Accessed 2026-05-17.